Filter Results:
(1,252)
Show Results For
- All HBS Web
(1,252)
- People (5)
- News (167)
- Research (918)
- Events (6)
- Multimedia (12)
- Faculty Publications (752)
Show Results For
- All HBS Web
(1,252)
- People (5)
- News (167)
- Research (918)
- Events (6)
- Multimedia (12)
- Faculty Publications (752)
- December 1992 (Revised September 1996)
- Case
ImmuLogic Pharmaceutical Corporation (Abridged)
By: Josh Lerner
ImmuLogic Pharmaceutical Corp., a development-stage biotechnology company, is considering making an initial offering of common stock. The rationales for and problems of high-technology start-ups are explored. The challenges posed by "windows" for public offerings are... View Details
Keywords: Decisions; Initial Public Offering; Entrepreneurship; Going Public; Business Startups; Pharmaceutical Industry; Pharmaceutical Industry; United States
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (Abridged)." Harvard Business School Case 293-087, December 1992. (Revised September 1996.)
- August 2012 (Revised August 2024)
- Case
ABC Pharmaceuticals
By: Regina E. Herzlinger and Erik R. Sparks
This case asks students to price a new drug that is in Stage II of its clinical trials. It contains detailed estimates of the time required and costs for all the steps needed to commercialize a drug in the U.S. Students will learn virtually all the steps required to... View Details
Keywords: Drug Development; Price; Product; Product Launch; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Herzlinger, Regina E., and Erik R. Sparks. "ABC Pharmaceuticals." Harvard Business School Case 313-041, August 2012. (Revised August 2024.)
- September 1991 (Revised August 1994)
- Background Note
Note on Pharmaceutical Industry Regulation
Traces the evolution of U.S. regulatory policy towards the pharmaceutical industry over the course of the twentieth century. A major theme is the steady shift away from a policy of 'let the buyer beware' to the creation of a complex and time-consuming review process,... View Details
Keywords: Safety; Industry Growth; Marketing; Research and Development; Health Testing and Trials; Economics; Pharmaceutical Industry; United States
Emmons, Willis M., III. "Note on Pharmaceutical Industry Regulation." Harvard Business School Background Note 792-002, September 1991. (Revised August 1994.)
- December 1985 (Revised July 1992)
- Supplement
Pennsylvania Pharmaceuticals (B)
By: Michael Beer
Beer, Michael. "Pennsylvania Pharmaceuticals (B)." Harvard Business School Supplement 486-074, December 1985. (Revised July 1992.)
- December 1985 (Revised July 1992)
- Case
Pennsylvania Pharmaceuticals (A)
By: Michael Beer
Keywords: Pharmaceutical Industry
Beer, Michael. "Pennsylvania Pharmaceuticals (A)." Harvard Business School Case 486-073, December 1985. (Revised July 1992.)
- September 1987 (Revised November 1991)
- Case
International Pharmaceuticals Inc.
By: W. Carl Kester and Richard P. Melnick
Keywords: Pharmaceutical Industry
Kester, W. Carl, and Richard P. Melnick. "International Pharmaceuticals Inc." Harvard Business School Case 288-011, September 1987. (Revised November 1991.)
- October 1992 (Revised November 1997)
- Case
ImmuLogic Pharmaceutical Corporation (A): March 1991
By: Josh Lerner
ImmuLogic Pharmaceutical Corp., a development-stage biotechnology company, is considering making an initial offering of common stock. The diverse perspectives of the entrepreneur, venture capitalist, investment banker, and institutional investor are explored. Problems... View Details
Keywords: Decisions; Entrepreneurship; Venture Capital; Banks and Banking; Initial Public Offering; Going Public; Perspective; Valuation; Pharmaceutical Industry; Pharmaceutical Industry
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (A): March 1991." Harvard Business School Case 293-066, October 1992. (Revised November 1997.)
- October 2012
- Teaching Plan
Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech (TP)
By: Robert F. Higgins
This is the teaching note related to HBS case 808005. In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would improve the flow of novel drug candidates... View Details
Keywords: Venture Philanthropy; Biotechnology; Funding Philanthropy Venture; Cystic Fibrosis; Foundations; Pharmaceuticals; Mergers and Acquisitions; For-Profit Firms; Venture Capital; Philanthropy and Charitable Giving; Science-Based Business; Nonprofit Organizations; Pharmaceutical Industry; Pharmaceutical Industry; United States; San Diego
- January 2006 (Revised May 2007)
- Case
Endo Pharmaceuticals (A): From LBO to...?
By: Richard G. Hamermesh and Brian DeLacey
Endo Pharmaceuticals was formed in 1997 as a leveraged buyout spin-off from DuPont Merck. In 1999, it must decide whether to do an IPO or merge with a smaller company. View Details
Keywords: Private Equity; Initial Public Offering; Leveraged Buyouts; Mergers and Acquisitions; Health Care and Treatment; Pharmaceutical Industry; United States
Hamermesh, Richard G., and Brian DeLacey. "Endo Pharmaceuticals (A): From LBO to...?" Harvard Business School Case 806-064, January 2006. (Revised May 2007.)
- January 1955
- Case
Fischer Pharmaceutical Co.
By: Charles M. Williams
Williams, Charles M. "Fischer Pharmaceutical Co." Harvard Business School Case 255-004, January 1955.
- September 2006 (Revised March 2010)
- Case
Teva Pharmaceutical Industries, Ltd
By: Tarun Khanna, Krishna G. Palepu and Claudine Deborah Madras
How do companies develop a strategy that is both low-cost and differentiated without becoming squeezed in the middle? Describes how Teva, Israel's first and largest multinational, achieved its globally dominant position in generic pharmaceuticals, an industry that has... View Details
Keywords: Multinational Firms and Management; Emerging Markets; Rank and Position; Competitive Strategy; Pharmaceutical Industry; India; Israel
Khanna, Tarun, Krishna G. Palepu, and Claudine Deborah Madras. "Teva Pharmaceutical Industries, Ltd." Harvard Business School Case 707-441, September 2006. (Revised March 2010.)
- September 1999 (Revised September 2005)
- Case
Strategic Deal Making at Millennium Pharmaceuticals
A small start-up in 1993, Millennium Pharmaceuticals was a name-brand biotechnology company by the end of 1998, with a market capitalization of $1.4 billion. The Cambridge-based company's growth strategy had relied heavily on building alliances for early-stage drug... View Details
Keywords: Alliances; Negotiation Deal; Growth and Development Strategy; Pharmaceutical Industry; Cambridge
Watkins, Michael D., and Sarah Matthews. "Strategic Deal Making at Millennium Pharmaceuticals." Harvard Business School Case 800-032, September 1999. (Revised September 2005.)
- January 1995 (Revised July 1996)
- Case
Pharmaceutical Industry in the 1990s, The
Describes the pharmaceutical industry in the 1990s, with particular emphasis on the mergers between American manufacturers and prescription-benefits managers (PBMs). PBMs are distributors with unprecedented access to information on patient and physician... View Details
Keywords: Knowledge Use and Leverage; Distribution; Mergers and Acquisitions; Knowledge Management; Pharmaceutical Industry; Pharmaceutical Industry; United States
McGahan, Anita M., Greg Keller, and John F. McGuire. "Pharmaceutical Industry in the 1990s, The." Harvard Business School Case 796-058, January 1995. (Revised July 1996.)
- October 2005 (Revised January 2021)
- Case
Pharmaceutical Industry in 2005, The
By: John R. Wells and Elizabeth Raabe
The entire pharmaceutical industry faced uncertain times in 2005. Many of the industry's most pressing issues—patent expirations, new drug pipeline development, price pressures, regulatory issues, and political pressures—were long standing. Fundamentally new... View Details
Keywords: Strategy; Research and Development; Framework; Change; Competition; Technological Innovation; Pharmaceutical Industry
Wells, John R., and Elizabeth Raabe. "Pharmaceutical Industry in 2005, The." Harvard Business School Case 706-423, October 2005. (Revised January 2021.)
- June 2007
- Teaching Note
Endo Pharmaceuticals Series (TN)
By: Richard G. Hamermesh, Brian DeLacey and Erin Seefeld
Keywords: Information
- August 1994
- Case
Yamanouchi Pharmaceutical Co., Ltd.
By: Robin Cooper and Robert S. Kaplan
Cooper, Robin, and Robert S. Kaplan. "Yamanouchi Pharmaceutical Co., Ltd." Harvard Business School Case 195-086, August 1994.
- November 2007
- Supplement
Teva Pharmaceutical Industries, Ltd.
By: Tarun Khanna and Krishna G. Palepu
How do companies develop a strategy that is both low-cost and differentiated without becoming squeezed in the middle? Describes how Teva, Israel's largest and first multinational, achieved its globally dominant position in generic pharmaceuticals, an industry that has... View Details
Keywords: Multinational Firms and Management; Emerging Markets; Rank and Position; Competitive Strategy; Pharmaceutical Industry; Israel; India
Khanna, Tarun, and Krishna G. Palepu. "Teva Pharmaceutical Industries, Ltd." Harvard Business School Video Supplement 708-806, November 2007.
- July 1992 (Revised April 1995)
- Background Note
Swiss Pharmaceutical Industry, The
Enright, Michael J. "Swiss Pharmaceutical Industry, The." Harvard Business School Background Note 793-029, July 1992. (Revised April 1995.)
- Research Summary
Marketing and Competition in Pharmaceutical Markets
In his research on pharmaceutical markets, Professor King explores how marketing and product differentiation affect competition among firms in the prescription market for anti-ulcer drugs. Four main results emerge from an analysis of antiulcer drug sales from 1977 to... View Details
- 11 Oct 2011
- Working Paper Summaries